Abstract

Background: Delayed cerebral ischemia and cerebral vasospasm remain the leading causes of poor outcome in survivors of aneurysmal subarachnoid hemorrhage. Refractory cerebral vasospasms can be treated with endovascular vasodilator therapy, which can either be performed in conscious sedation or general anesthesia. The aim of this study is to compare the effect of the anesthesia modality on long-term clinical outcomes in patients undergoing endovascular vasodilator therapy due to cerebral vasospasm and hypoperfusion. Methods: Modified Rankin Scale (mRS) scores were retrospectively analyzed at time of discharge from the hospital and six months after aneurysmal subarachnoid hemorrhage. Additionally, National Institutes of Health Stroke Scale (NIHSS) was assessed 24 hours before, immediately before, immediately after, and 24 hours after endovascular vasodilator therapy, and at discharge and six months. Interventional parameters such as duration of intervention, choice and dosage of vasodilator and number of arteries treated were also recorded. Results: A total of 98 patients were included in this analysis and separated into patients who had interventions in conscious sedation, general anesthesia and a mix of both. Neither mRS at discharge nor at six months showed a significant difference for functionally independent outcomes (mRS 0-2) between groups. NIHSS before endovascular vasodilator therapy was significantly higher in patients receiving interventions in general anesthesia but did not differ anymore between groups six months after the initial bleed. Conclusion: This study did not observe a difference in outcome whether patients underwent endovascular vasodilator therapy in general anesthesia or conscious sedation for refractory cerebral vasospasms. Hence, the choice should be made for each patient individually.

Highlights

  • Cerebral vasospasms (CVS) and delayed cerebral ischemia still remain among the leading causes of morbidity and mortality in survivors of aneurysmal subarachnoid hemorrhage

  • In total, 109 patients with refractory CVS treated by intra-arterial admission of either nimodipine and/or papaverine between September 2011 and October 2019 at the University Hospital Bern, Bern, Switzerland were included

  • Neither choice and dosage of intra-arterial vasodilator, nor number of treated arteries showed significant differences between groups. This retrospective study found no significant differences in functionally independent outcomes six months after aneurysmal subarachnoid hemorrhage (aSAH) in patients who were treated with intra-arterial vasodilators in conscious sedation (CS), general anesthesia (GA) or a combination of both

Read more

Summary

Introduction

Cerebral vasospasms (CVS) and delayed cerebral ischemia still remain among the leading causes of morbidity and mortality in survivors of aneurysmal subarachnoid hemorrhage (aSAH). Delayed cerebral ischemia and cerebral vasospasm remain the leading causes of poor outcome in survivors of aneurysmal subarachnoid hemorrhage. National Institutes of Health Stroke Scale (NIHSS) was assessed 24 hours before, immediately before, immediately after, and 24 hours after endovascular vasodilator therapy, and at discharge and six months. Interventional parameters such as duration of intervention, choice and dosage of vasodilator and number of arteries treated were recorded. NIHSS before endovascular vasodilator therapy was significantly higher in patients version 2

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call